Yes, this is long... I am trying to wrap my hea
Post# of 30028
Posted On: 01/28/2015 6:41:25 PM
Yes, this is long...
I am trying to wrap my head around today's Blog. GC never simply puts out an "informative" blog. It is a roadmap or at the very least a breadcrumb trail of where they are headed!!!
As example...
Dec.22
One of leading researchers in the field, Dr. Howard Federoff - See more at: http://www.thechairmansblog.com/amarantus-bio...ORoZP.dpuf
Jan.15
Amarantus Announces Exclusive Option Agreement With Georgetown University to License Patent Rights for Blood Based Biomarkers for Alzheimer's Disease
http://ir.amarantus.com/company-news/detail/1...rs-disease
Today's Blog
...what is truly frightening for baby boomers, insurance companies and policy makers is the fact that this figure is expected to increase six-fold (yes, 6x) to $1.2 trillion ($1,200,000,000) annually by 2050. This projection could essentially bankrupt the United States , the largest economy in the world, along with all of the world’s leading global economies in fewer than forty years
(painting a picture of pandemic that IS unfolding)
The FDA , key opinion leading (KOL) physicians and politicians all agree that the first critical step in bending this astronomical cost curve for AD is to be able to identify patients with very early disease, perhaps even before symptoms develop, and test new experimental treatments while monitoring their potential effectiveness with objective, easy-to-use biomarkers – ideally blood biomarkers -
This esteemed group includes a scientist and clinicians with extensive experience in Big Pharma, academia, and collaborating with small biopharmaceutical companies and government organizations . We believe this initial group of individuals will not only help Amarantus Diagnostics gain access to the right contacts in the Alzheimer’s groups at companies and government agencies
we focused on diseases where better diagnostic information would both improve medical outcomes for patients, while simultaneously reducing overall healthcare costs ( the ]mantra of the Affordable Care Act that now governs the U.S. healthcare system )
And here is where I see the bidding starting!
peak near-term revenue potential of $300 million in the U.S. alone
If anyone is looking to "partner" or buy a majority stake in AMBSDX, their first offer must beat 300mm for ALZ testing and MSpre. alone. Maybe we give them ROW but includes royalties & or milestone payments to us, add to that our other DX's we're are adding to AMBSDX, multiply by forward earnings (which look to be around 3 Bil long term)
We intend to focus on maintaining a significant financial interest in the diagnostics business because we wholeheartedly believe Amarantus Diagnostics can “win” in Alzheimer’s disease and multiple sclerosis
I don't see how they can focus on (single out) "long term" shareholders unless they announce some sort of deal that benefit shareholders that own shares they day they announce.
A lot to digest, for me at least... I just see this as a very stern but fair warning shot!
Sorry for the long post, I just may be "rambling" as well....
Cheers
I am trying to wrap my head around today's Blog. GC never simply puts out an "informative" blog. It is a roadmap or at the very least a breadcrumb trail of where they are headed!!!
As example...
Dec.22
One of leading researchers in the field, Dr. Howard Federoff - See more at: http://www.thechairmansblog.com/amarantus-bio...ORoZP.dpuf
Jan.15
Amarantus Announces Exclusive Option Agreement With Georgetown University to License Patent Rights for Blood Based Biomarkers for Alzheimer's Disease
http://ir.amarantus.com/company-news/detail/1...rs-disease
Today's Blog
...what is truly frightening for baby boomers, insurance companies and policy makers is the fact that this figure is expected to increase six-fold (yes, 6x) to $1.2 trillion ($1,200,000,000) annually by 2050. This projection could essentially bankrupt the United States , the largest economy in the world, along with all of the world’s leading global economies in fewer than forty years
(painting a picture of pandemic that IS unfolding)
The FDA , key opinion leading (KOL) physicians and politicians all agree that the first critical step in bending this astronomical cost curve for AD is to be able to identify patients with very early disease, perhaps even before symptoms develop, and test new experimental treatments while monitoring their potential effectiveness with objective, easy-to-use biomarkers – ideally blood biomarkers -
This esteemed group includes a scientist and clinicians with extensive experience in Big Pharma, academia, and collaborating with small biopharmaceutical companies and government organizations . We believe this initial group of individuals will not only help Amarantus Diagnostics gain access to the right contacts in the Alzheimer’s groups at companies and government agencies
we focused on diseases where better diagnostic information would both improve medical outcomes for patients, while simultaneously reducing overall healthcare costs ( the ]mantra of the Affordable Care Act that now governs the U.S. healthcare system )
And here is where I see the bidding starting!
peak near-term revenue potential of $300 million in the U.S. alone
If anyone is looking to "partner" or buy a majority stake in AMBSDX, their first offer must beat 300mm for ALZ testing and MSpre. alone. Maybe we give them ROW but includes royalties & or milestone payments to us, add to that our other DX's we're are adding to AMBSDX, multiply by forward earnings (which look to be around 3 Bil long term)
We intend to focus on maintaining a significant financial interest in the diagnostics business because we wholeheartedly believe Amarantus Diagnostics can “win” in Alzheimer’s disease and multiple sclerosis
I don't see how they can focus on (single out) "long term" shareholders unless they announce some sort of deal that benefit shareholders that own shares they day they announce.
A lot to digest, for me at least... I just see this as a very stern but fair warning shot!
Sorry for the long post, I just may be "rambling" as well....
Cheers
(0)
(0)Amarantus Bioscience Holdings (AMBS) Stock Research Links
Scroll down for more posts ▼